Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present
with concomitant ischemic heart disease and often require coronary angiography with or
without percutaneous coronary intervention (PCI). The decision whether to continue the DOAC
throughout periprocedural period or interrupt DOAC before planned procedure represents a
substantial challenge in daily clinical practice.
The objective of this study is to evaluate the safety of uninterrupted direct-acting oral
anticoagulation in patients undergoing trans-radial percutaneous coronary procedures.